Synaptogenix Inc (SNPX)

[runncoach]

No doubt the 42 week secondary endpoint it exploratory. It might tell you or me or Alkon something and it might could be used for an additional P3 design but my understanding is there are no measurements between week 28 and 42 so IMO any info gained would be kind of an informed "guess" based on a single point in time. It will be interesting to see what the placebo does during that time and it will be interesting to see how long the bryostatin test scores remain above baseline, but I'm not sure how useful it will be on developing a dosing schedule past 28 weeks to be honest. As you say, that isn't necessarily needed since we are using the memantine 28 week study as our guide. That 42 week, secondary endpoint is delaying the trial conclusion by 3 months. I guess it could be argued if the scores fall during the 3 month extension that its due to the lack of drug dosing so bryostatin must be working, and if it stays above baseline without dosing that the its working due to synaptic regrowth. Win/win maybe lol.